1
|
Lee JH, Kim GB, Han K, Jung EJ, Suh HJ, Jo K. Efficacy and safety of galacto-oligosaccharide in the treatment of functional constipation: randomized clinical trial. Food Funct 2024; 15:6374-6382. [PMID: 38787732 DOI: 10.1039/d4fo00999a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2024]
Abstract
The efficacy and safety of galacto-oligosaccharides (GOS) in treating functional constipation were evaluated in a four-week randomized, double-blind clinical trial on 63 patients who met Rome IV criteria (34 GOS, 29 placebo group). The number of bowel movements per day and changes in the shape of bowel movements in the treatment group significantly improved compared to those in the control group after four weeks. The Patient Assessment Constipation Quality of Life questionnaire showed that satisfaction with constipation significantly increased in the treatment group. The levels of Bifidobacterium sp. and Lactobacillus sp. significantly increased after four weeks of GOS treatment compared to those measured at baseline. No significant adverse drug reactions were identified in any indicator except for pulse rate. Thus, the prebiotic GOS can be safely used in foods and pharmaceuticals to alleviate symptoms of functional constipation by improving the intestinal flora.
Collapse
Affiliation(s)
- Jae-Hwan Lee
- Department of Animal Science and Technology, Chung-Ang University, Anseong 17546, Republic of Korea
| | - Geun-Bae Kim
- Department of Animal Science and Technology, Chung-Ang University, Anseong 17546, Republic of Korea
| | - Kisoo Han
- NeoCremar Co. Ltd, Seoul 05702, Republic of Korea
| | - Eun-Jin Jung
- Department of Food and Biotechnology, Korea University, Sejong 30019, Republic of Korea
| | - Hyung Joo Suh
- Transdisciplinary Major in Learning Health Systems, Graduate School, Korea University, Seoul 02841, Republic of Korea
- Department of Integrated Biomedical and Life Science, Graduate School, Korea University, Seoul 02841, Republic of Korea.
| | - Kyungae Jo
- Department of Integrated Biomedical and Life Science, Graduate School, Korea University, Seoul 02841, Republic of Korea.
| |
Collapse
|
2
|
You S, Ma Y, Yan B, Pei W, Wu Q, Ding C, Huang C. The promotion mechanism of prebiotics for probiotics: A review. Front Nutr 2022; 9:1000517. [PMID: 36276830 PMCID: PMC9581195 DOI: 10.3389/fnut.2022.1000517] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Accepted: 08/31/2022] [Indexed: 12/18/2022] Open
Abstract
Prebiotics and probiotics play a positive role in promoting human nutrition and health. Prebiotics are compounds that cannot be digested by the host, but can be used and fermented by probiotics, so as to promote the reproduction and metabolism of intestinal probiotics for the health of body. It has been confirmed that probiotics have clinical or health care functions in preventing or controlling intestinal, respiratory, and urogenital infections, allergic reaction, inflammatory bowel disease, irritable bowel syndrome and other aspects. However, there are few systematic summaries of these types, mechanisms of action and the promotion relationship between prebiotics and probiotic. Therefore, we summarized the various types of prebiotics and probiotics, their individual action mechanisms, and the mechanism of prebiotics promoting probiotics in the intestinal tract. It is hoped this review can provide new ideas for the application of prebiotics and probiotics in the future.
Collapse
Affiliation(s)
- Siyong You
- Co-Innovation Center for Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing, China
- Department of Food Science and Technology, National University of Singapore, Singapore, Singapore
| | - Yuchen Ma
- Co-Innovation Center for Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing, China
- Food Science and Technology Center, National University of Singapore (Suzhou) Research Institute, Suzhou, China
| | - Bowen Yan
- Co-Innovation Center for Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing, China
| | - Wenhui Pei
- Co-Innovation Center for Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing, China
| | - Qiming Wu
- Nutrilite Health Institute, Shanghai, China
- *Correspondence: Qiming Wu
| | - Chao Ding
- Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China
- Chao Ding
| | - Caoxing Huang
- Co-Innovation Center for Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing, China
- Caoxing Huang
| |
Collapse
|
3
|
Cai Y, van Putten JP, Gilbert MS, Gerrits WJ, Folkerts G, Braber S. Galacto-oligosaccharides as an anti-bacterial and anti-invasive agent in lung infections. Biomaterials 2022; 283:121461. [DOI: 10.1016/j.biomaterials.2022.121461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2021] [Revised: 02/10/2022] [Accepted: 03/05/2022] [Indexed: 11/02/2022]
|
4
|
Baek Y, Ahn Y, Shin J, Suh HJ, Jo K. Evaluation of Safety through Acute and Subacute Tests of Galacto-Oligosaccharide (GOS). Prev Nutr Food Sci 2021; 26:315-320. [PMID: 34737992 PMCID: PMC8531431 DOI: 10.3746/pnf.2021.26.3.315] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 04/23/2021] [Indexed: 11/28/2022] Open
Abstract
Acute and subacute toxicity tests were undertaken on a novel galacto-oligosaccharide (GOS) produced from lactose by β-galactosidase derived from Bacillus circulans. Toxicity was evaluated by single dose oral administration (5,000 mg/kg) and was repeated at day 28 (1,000 mg/kg) in male and female Sprague-Dawley rats. In acute toxicity tests, the protein levels of male rats administered GOS showed a significant difference from controls, but remained within the normal range. There were no GOS-related changes in clinical symptoms, weight, food intake, hematology, blood chemistry, relative organ weight, or severe pathology in rats treated with GOS compared with controls. The no observed adverse effect level of GOS was at least 1,000 mg/kg/d in both male and female rats. Bovine-specific genes were not detected in GOS 70%-based products (NeoGOS-P70, NeoGOS-L70, and organic GOS), indirectly showing the absence of an allergen and that products containing GOS 70% are non-toxic and allergen-free.
Collapse
Affiliation(s)
- Youngjin Baek
- Department of Integrated Biomedical and Life Science, Graduate School, Korea University, Seoul 02841, Korea.,Department of R&D, Neo Cremar Co., Ltd., Seoul 05702, Korea
| | - Yejin Ahn
- Department of Integrated Biomedical and Life Science, Graduate School, Korea University, Seoul 02841, Korea
| | - Jungcheul Shin
- Department of R&D, Neo Cremar Co., Ltd., Seoul 05702, Korea
| | - Hyung Joo Suh
- Department of Integrated Biomedical and Life Science, Graduate School, Korea University, Seoul 02841, Korea
| | - Kyungae Jo
- Department of Integrated Biomedical and Life Science, Graduate School, Korea University, Seoul 02841, Korea
| |
Collapse
|
5
|
Ambrogi V, Bottacini F, Cao L, Kuipers B, Schoterman M, van Sinderen D. Galacto-oligosaccharides as infant prebiotics: production, application, bioactive activities and future perspectives. Crit Rev Food Sci Nutr 2021; 63:753-766. [PMID: 34477457 DOI: 10.1080/10408398.2021.1953437] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Galacto-oligosaccharides (GOS) are non-digestible oligosaccharides characterized by a mix of structures that vary in their degree of polymerization (DP) and glycosidic linkage between the galactose moieties or between galactose and glucose. They have enjoyed extensive scientific scrutiny, and their health-promoting effects are supported by a large number of scientific and clinical studies. A variety of GOS-associated health-promoting effects have been reported, such as growth promotion of beneficial bacteria, in particular bifidobacteria and lactobacilli, inhibition of pathogen adhesion and improvement of gut barrier function. GOS have attracted significant interest from food industries for their versatility as a bioactive ingredient and in particular as a functional component of infant formulations. These oligosaccharides are produced in a kinetically-controlled reaction involving lactose transgalactosylation, being catalyzed by particular β-galactosidases of bacterial or fungal origin. Despite the well-established technology applied for GOS production, this process may still meet with technological challenges when employed at an industrial scale. The current review will cover relevant scientific literature on the beneficial physiological properties of GOS as a prebiotic for the infant gut microbiota, details of GOS structures, the associated reaction mechanism of β-galactosidase, and its (large-scale) production.
Collapse
Affiliation(s)
- Valentina Ambrogi
- School of Microbiology, University College Cork, Cork, Ireland.,APC Microbiome Ireland, University College Cork, Cork, Ireland
| | - Francesca Bottacini
- APC Microbiome Ireland, University College Cork, Cork, Ireland.,Department of Biological Sciences, Munster Technological University, Cork, Ireland
| | - Linqiu Cao
- FrieslandCampina, Amersfoort, The Netherlands
| | - Bas Kuipers
- FrieslandCampina, Amersfoort, The Netherlands
| | | | - Douwe van Sinderen
- School of Microbiology, University College Cork, Cork, Ireland.,APC Microbiome Ireland, University College Cork, Cork, Ireland
| |
Collapse
|
6
|
Jain M, Kaur M, Tiwari DP, Vishwanath C, Javaregowda N, Chandrayan G, Bhoite PY, Krishnappa M, Dubey AK. Juvenile toxicity study of Gossence™ (galactooligosaccharides) in Sprague Dawley rats. TOXICOLOGY RESEARCH AND APPLICATION 2020. [DOI: 10.1177/2397847320913213] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Gossence™ (galactooligosaccharide; GOS) is a prebiotics and used as one of the major constituents in infant milk formulas that act as a functional food. Gossence is manufactured by Tata Chemicals Ltd, India, through a patented process of biotransformation of lactose. A toxicology study in juvenile rats was carried out to assess the safety profile of Gossence intended for pediatric population. The objective of this study is to assess the potential systemic toxicity of Gossence when administered through gavage at dose levels of 1000, 2000, or 5000/3000 mg/kg/day (equivalent to 1347, 2694, and 6735/4041 mg/kg/day of GOS, respectively) to juvenile Sprague Dawley rats from postnatal day (PND) 4 to PND 52 (i.e. total 49 days of dosing period). A separate group of animals were treated with vehicle (purified Milli Q water) for a similar duration. The following parameters were evaluated during the study period: morbidity/mortality check, clinical signs, body weights, body weight changes, food consumption, functional observational battery, motor activity, postnatal developmental observations, hematology, clinical chemistry, urinalysis, organ weight, gross pathology, and histopathology. During dosing phase, the high-dose group, 5000 mg/kg/day, was reduced to 3000 mg/kg/day (equivalent to 4041 mg/kg/day dose of GOS) from day 16 (PND 19) onward, due to clinical signs of watery feces and yellow color stains at urogenital region and mortality in two animals on day 15 (PND 18) of the study. Time-weighted average dose for 5000 mg/kg/day was equivalent to 3600 mg/kg/day. No further deaths or clinical signs were noticed in animals at 3000 mg/kg/day from day 18 (PND 21) of dosing phase to until terminal euthanization. At the terminal euthanization, there were no test item-related gross changes observed in all surviving rats except for, an increased cecum size in some of the rats at 5000/3000 mg/kg/day, which correlated with the increased weights of cecum with contents during organ weight recording, but this had no correlating light microscopic changes during histological examination. The cecal enlargement was completely recovered following the 14-day recovery period. The no-observedadverse-effect level is 3000 mg/kg/day for Gossence, which is equivalent to 4041 mg/kg/day of GOS in both sexes.
Collapse
Affiliation(s)
- Manish Jain
- Tata Chemicals Limited–Innovation Centre, Pune, Maharashtra, India
| | - Moninder Kaur
- Tata Chemicals Limited–Innovation Centre, Pune, Maharashtra, India
| | | | | | - Nataraju Javaregowda
- Department of Safety Assessment, Syngene International Limited, Bangalore, Karnataka, India
| | - Govind Chandrayan
- Department of Safety Assessment, Syngene International Limited, Bangalore, Karnataka, India
| | - Prabhakar Y Bhoite
- Department of Safety Assessment, Syngene International Limited, Bangalore, Karnataka, India
| | - Mohan Krishnappa
- Department of Safety Assessment, Syngene International Limited, Bangalore, Karnataka, India
| | | |
Collapse
|
7
|
Pitt J, Chan M, Gibson C, Hasselwander O, Lim A, Mukerji P, Mukherjea R, Myhre A, Sarela P, Tenning P, Himmelstein MW, Roper JM. Safety assessment of the biotechnologically produced human-identical milk oligosaccharide 3-Fucosyllactose (3-FL). Food Chem Toxicol 2019; 134:110818. [PMID: 31533061 DOI: 10.1016/j.fct.2019.110818] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Revised: 09/09/2019] [Accepted: 09/12/2019] [Indexed: 10/26/2022]
Abstract
3-Fucosyllactose (3-FL), a highly abundant complex carbohydrate in human breast milk, functions as a prebiotic promoting early microbial colonization of the gut, increasing pathogen resistance and modulating immune responses. To investigate potential health benefits, 3-FL was produced by fermentation using a genetically modified E. coli K12 strain. The safety assessment of 3-FL included acute oral toxicity, in vitro and in vivo assessment of genetic toxicity, and a subchronic rodent feeding study. 3-FL was not acutely toxic at 5000 mg/kg bw, and there was no evidence of genetic toxicity in the bacterial reverse mutation test and chromosomal aberration assay. There was a repeatable statistically-significant trend in the 4-h S9-activated test conditions in the in vitro micronucleus assay; the confirmatory in vivo mouse micronucleus study was negative at all doses. Dietary subchronic exposure of rats to 3-FL (5% and 10%) did not produce any statistical or biologically-relevant differences in growth, food intake or efficiency, clinical observations, or clinical or anatomic pathology changes at average daily intakes of 5.98 and 7.27 g/kg bw/day for males and females, respectively. The weight of evidence from these studies support the safe use of 3-FL produced using biotechnology as a nutritional ingredient in foods.
Collapse
Affiliation(s)
- J Pitt
- DuPont Nutrition and Biosciences, 1801 Larkin Center Drive, Midland, MI, 48674, USA.
| | - M Chan
- Corteva™, Agriscience™, P.O. Box 30, Newark, DE, 19714, USA
| | - C Gibson
- Total Pathology Solutions, LLC, Kennett Square, PA, 19348, USA
| | - O Hasselwander
- DuPont Nutrition and Biosciences, 43 London Road, Reigate, Surrey, RH2 9PW, UK
| | - A Lim
- DuPont Nutrition and Biosciences, 200 Powder Mill Road, Wilmington, DE, 19803, USA
| | - P Mukerji
- Corteva™, Agriscience™, P.O. Box 30, Newark, DE, 19714, USA
| | - R Mukherjea
- DuPont Nutrition and Biosciences, 4300 Duncan Ave, St. Louis MO, 63110, USA
| | - A Myhre
- Corteva™, Agriscience™, P.O. Box 30, Newark, DE, 19714, USA
| | - P Sarela
- DuPont Nutrition and Biosciences, Sokeritehtaanti 20, FI- 02460, Kantvik, FI, USA
| | - P Tenning
- DuPont Nutrition and Biosciences, Langebrogade 1, DK-1411, Copenhagen K, DE, USA
| | | | - J M Roper
- Corteva™, Agriscience™, P.O. Box 30, Newark, DE, 19714, USA
| |
Collapse
|
8
|
Jain M, Narayanan S, Tiwari DP, Ranjan B, Jadhav A, Venkataramulu D, Chandrayan G, Jayarao C, Bhoite P, Krishnappa M, Dubey AK. Safety assessment of Gossence™ (galactooligosaccharides): Genotoxicity and general toxicity studies in Sprague Dawley rats. TOXICOLOGY RESEARCH AND APPLICATION 2019. [DOI: 10.1177/2397847319860375] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Galactooligosaccharides (GOS) used as prebiotics are one of the major constituents of the infant milk formulas. GOS (Gossence™) is produced by a patented process of biotransformation of lactose; hence toxicology studies were carried out to assess its safety. The objective of the present study was to evaluate the general and genetic toxicity of Gossence™. In 14-day and subchronic (90-day) oral toxicity studies in Sprague Dawley rats, daily administration of GOS at dose levels of 1000, 2000, or 5000 mg/kg (equivalent to 1347, 2694, and 6735 mg/kg/day of Gossence™, respectively) did not cause any mortality, or clinical signs, and changes in body weights, feed consumption, hematology, clinical chemistry, and urinalysis. In 90-day study, no changes in ophthalmological and neurological findings were observed. Significant increases in the cecum weights (with and/or without content) at dose levels of ≥2000 mg/kg were observed in both 14-day and 90-day studies. Based on the results of 90-day study, the no-observed-adverse-effect-level for GOS is 5000 mg/kg/day which is equivalent to 6735 mg Gossence™/kg/day. In the bacterial reverse mutation test, there was no significant increase in the mean numbers of revertants at the tested concentrations. Gossence™ was not mutagenic up to 5000 µg/plate. In chromosomal aberration test, there was no statistically significant increase in the number of percent aberrant metaphase for the Gossence™. Gossence™ is non-clastogenic (negative) in the in vitro chromosomal aberration test using human peripheral blood lymphocyte during short and prolonged treatment.
Collapse
Affiliation(s)
- Manish Jain
- Tata Chemicals Limited-Innovation Centre, Ambedveth (V), Mulshi, Pune, Maharashtra, India
| | - S Narayanan
- Tata Chemicals Limited-Innovation Centre, Ambedveth (V), Mulshi, Pune, Maharashtra, India
| | - Deepika Pandey Tiwari
- Tata Chemicals Limited-Innovation Centre, Ambedveth (V), Mulshi, Pune, Maharashtra, India
| | - Bibhuti Ranjan
- Department of Safety Assessment, Syngene International Limited, Bangalore, Karnataka, India
| | - Avinash Jadhav
- Department of Safety Assessment, Syngene International Limited, Bangalore, Karnataka, India
| | - Deepa Venkataramulu
- Department of Safety Assessment, Syngene International Limited, Bangalore, Karnataka, India
| | - Govind Chandrayan
- Department of Safety Assessment, Syngene International Limited, Bangalore, Karnataka, India
| | - Chaitra Jayarao
- Department of Safety Assessment, Syngene International Limited, Bangalore, Karnataka, India
| | - Prabhakar Bhoite
- Department of Safety Assessment, Syngene International Limited, Bangalore, Karnataka, India
| | - Mohan Krishnappa
- Department of Safety Assessment, Syngene International Limited, Bangalore, Karnataka, India
| | - Ashok Kumar Dubey
- Tata Chemicals Limited-Innovation Centre, Ambedveth (V), Mulshi, Pune, Maharashtra, India
| |
Collapse
|
9
|
Zhou Y, Kruger C, Ravi GS, Kumar DPS, Vijayasarathi SK, Lavingia M, Chen X, Ambriz P. Safety evaluation of galacto-oligosaccharides. TOXICOLOGY RESEARCH AND APPLICATION 2017. [DOI: 10.1177/2397847317715864] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Galacto-oligosaccharides (GOS) have been added to infant formulas and conventional foods as prebiotics all over the world. The present study was conducted to assess the subchronic toxicity of a GOS syrup (VITAGOS™) when administered orally by gavage daily at 0, 1020, 2041, and 4082 mg GOS syrup/kg/day to male and female Sprague-Dawley rats to deliver doses of 0, 500, 1000, and 2000 mg GOS/kg/day for 90 days. Throughout the entire treatment period, no abnormal clinical signs or mortalities were observed. Similarly, no test article-related toxicologically adverse findings were seen in body weight, feed consumption, ophthalmological findings, hematology, coagulation, clinical chemistry, urinalysis, organ weights, and gross pathology or histopathology. Significant increases in the cecum weight of males and females treated with 2000 mg GOS/kg/day were associated with mucosal hypertrophy/hyperplasia; no changes in the cecum were noted at lower doses. The organ weight and histopathological changes noted in the cecum are consistent with findings in rats administered other poorly digestible and fermentable substances; thus, this is considered to be an adaptive rather than toxic response. The No-Observed-Adverse-Effect-Levels for VITAGOS™ is 4082 mg GOS syrup/kg body weight/day or 2000 mg GOS/kg body weight/day.
Collapse
Affiliation(s)
- Yuting Zhou
- ChromaDex Spherix Consulting, Business Unit of ChromaDex, Inc., MD, USA
| | - Claire Kruger
- ChromaDex Spherix Consulting, Business Unit of ChromaDex, Inc., MD, USA
| | - GS Ravi
- Advinus Therapeutics Limited, Bengaluru, Karnataka, India
| | | | | | - Mayuri Lavingia
- Vitalus Nutrition Inc., Abbotsford, British Columbia, Canada
| | - Xiaoyan Chen
- Vitalus Nutrition Inc., Abbotsford, British Columbia, Canada
| | - Pamela Ambriz
- Vitalus Nutrition Inc., Abbotsford, British Columbia, Canada
| |
Collapse
|
10
|
Matsuki T, Tajima S, Hara T, Yahagi K, Ogawa E, Kodama H. Infant formula with galacto-oligosaccharides (OM55N) stimulates the growth of indigenous bifidobacteria in healthy term infants. Benef Microbes 2016; 7:453-61. [DOI: 10.3920/bm2015.0168] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
The objective of the study was to investigate whether an infant formula supplemented with galacto-oligosaccharides (GOS; OM55N) was able to stimulate the growth of indigenous bifidobacteria and to establish microbiota similar to that of breastfed infants. A randomised, double-blind, placebo-controlled trial was performed using 35 healthy term infants (31-54 days of age; 42±6 days) to determine whether infant formula with 0.3 g/dl GOS (OM55N) stimulated the growth of bifidobacteria in the infants’ guts. At the trial onset and 2 weeks after, the infants’ faecal samples were examined for microbiota composition (bacterial abundance and α-diversity) and faecal characteristics. Among the 35 infants, 5 were withdrawn and 8 were excluded from the final evaluation before breaking the blinding since the indigenous bifidobacteria were not detected at the trial onset. After 2 weeks, the abundance of Bifidobacteriaceae was significantly increased in the GOS feeding group compared to the control (+11.6±24.1% vs -3.9±13.0%; P=0.043). The Shannon index, which accounts for both abundance and evenness of the present species, was significantly decreased with GOS supplementation (-0.1±0.4 vs +0.4±0.4; P=0.014). Faecal characteristics such as pH and organic acids were similar in both groups, with no statistical differences. No adverse side effects related to the formula consumption were reported. Although the concentration of GOS was relatively low, the infant formula with GOS increased the abundance of bifidobacteria and resulted in a reduced α-diversity of the microbiota.
Collapse
Affiliation(s)
- T. Matsuki
- Yakult Central Institute, Basic Research Department, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - S. Tajima
- Yakult Central Institute, Basic Research Department, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - T. Hara
- Yakult Central Institute, Basic Research Department, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - K. Yahagi
- Yakult Central Institute, Basic Research Department, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - E. Ogawa
- Teikyo University School of Medicine, Department of Pediatrics, 2-11-1 Kaga, Itabashi-ku Tokyo 173-8605, Japan
| | - H. Kodama
- Teikyo University School of Medicine, Department of Pediatrics, 2-11-1 Kaga, Itabashi-ku Tokyo 173-8605, Japan
| |
Collapse
|
11
|
Vo TH, Le NH, Patel MS, Phan LT, Tran Minh NN. Acute allergic reactions in Vietnamese children after drinking a new milk product. Foodborne Pathog Dis 2014; 9:156-9. [PMID: 22315953 DOI: 10.1089/fpd.2011.1059] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
In early October 2009, pediatricians in hospitals in Ho Chi Minh City (HCMC) reported an unusual increase in the number of children presenting with an acute onset of itchy rash and some with breathing difficulties shortly after drinking milk products. The pediatricians considered the illness to be an allergic reaction to milk. The objective of our investigation was to identify the cause of this acute illness. Following early case reports, all hospitals in HCMC were requested to report cases of this illness. Parents were advised to take children with symptoms to a hospital immediately. A case-series was conducted to generate hypotheses on the possible causes of the illness and was followed by a case-control study to test the hypothesis. Parents of all cases and controls were interviewed face-to-face. The association between food items and the allergy was tested using conditional logistics regression. From 9 to 28 October 2009, 19 cases fulfilled the case definition, and 16 of the 17 cases included in the study had consumed milk supplemented with galacto-oligosaccharides (GOS) shortly before the onset of illness. Fifty age-matched, neighborhood controls were enrolled into the case control study. Of the 30 food items consumed by study participants in the preceding 24 h, only the odds ratio (OR) of milk supplemented with GOS was statistically significant: OR=34.0 (95% CI=3.9, 294.8). Laboratory tests of this milk product did not reveal any unusual properties, chemicals, or other toxic substances. This is the first report of an acute allergic reaction to fresh milk supplemented with GOS. However, the specific allergen in this product was not identified. Further cases were not reported once this product was withdrawn from sale. Vietnam's food safety authorities should expand laboratory capacity to detect allergens in food products.
Collapse
Affiliation(s)
- Thuan Huu Vo
- Institute of Hygiene and Public Health, Ho Chi Minh City, Vietnam.
| | | | | | | | | |
Collapse
|
12
|
Narumi K, Takasawa H, Ohyama W, Kaneko K. In vivo comet assay of a novel galacto-oligosaccharide in rats. Hum Exp Toxicol 2014; 33:488-95. [DOI: 10.1177/0960327113506236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A novel galacto-oligosaccharide (GOS) manufactured by a two-step enzyme reaction of lactose was examined in a comet assay for its potential to induce DNA damage in vivo by estimating the DNA fragmentation level in the cellular nuclei of the glandular stomach, colon, and peripheral blood. GOS was orally administered at doses of 0 (vehicle alone), 500, 1000, and 2000 mg/kg/day to five male Crl: CD(Sprague Dawley) rats per group three times (48, 24, and 3 h before the animals were terminated). The specimens were prepared in accordance with the standard protocol (version 14.2) of the “International Validation of the In Vivo Rodent Alkaline Comet Assay for the Detection of Genotoxic Carcinogens” organized by the Japanese Center for the Validation of Alternative Methods. No significant differences in the percentage of DNA in the tail were observed between the GOS-treated groups and vehicle controls in any of the organs evaluated. Additionally, no GOS-related clinical signs or effects on body weight were seen. Based on these results, the comet assay of GOS in the glandular stomach, colon, and peripheral blood using rats was judged negative. Therefore, it is concluded that GOS did not induce DNA damage in vivo under the conditions employed in this study.
Collapse
Affiliation(s)
- K Narumi
- Yakult Central Institute for Microbiological Research, Yakult Honsha Co. Ltd, Kunitachi-shi, Tokyo, Japan
| | - H Takasawa
- Mitsubishi Chemical Mediance Corporation, Tokyo, Japan
| | - W Ohyama
- Yakult Central Institute for Microbiological Research, Yakult Honsha Co. Ltd, Kunitachi-shi, Tokyo, Japan
| | - K Kaneko
- Yakult Central Institute for Microbiological Research, Yakult Honsha Co. Ltd, Kunitachi-shi, Tokyo, Japan
| |
Collapse
|
13
|
Coulet M, Phothirath P, Allais L, Schilter B. Pre-clinical safety evaluation of the synthetic human milk, nature-identical, oligosaccharide 2′-O-Fucosyllactose (2′FL). Regul Toxicol Pharmacol 2014; 68:59-69. [DOI: 10.1016/j.yrtph.2013.11.005] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2013] [Revised: 11/06/2013] [Accepted: 11/09/2013] [Indexed: 12/26/2022]
|
14
|
Kaneko K, Watanabe Y, Kimura K, Matsumoto K, Mizobuchi T, Onoue M. Development of hypoallergenic galacto-oligosaccharides on the basis of allergen analysis. Biosci Biotechnol Biochem 2014; 78:100-8. [DOI: 10.1080/09168451.2014.877819] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Abstract
Galacto-oligosaccharides (GOSs) are recognized as prebiotics beneficial to human health through their abilities to modulate gut microbiota. On the other hand, it has been reported that immediate allergic reactions are caused by a GOS product (Bc-GOS) produced by treating lactose with β-galactosidase derived from Bacillus circulans. The objective of this study was to create a safer GOS product that is less likely to cause GOS-induced allergy (GOS-AL). First, we identified two derivatives of tetrasaccharide sugar chains in Bc-GOS as the factors responsible for GOS-AL by histamine release test (HRT) using blood samples obtained from two GOS-AL patients. Through our search for non-allergic GOS, we developed a new GOS product, SK-GOS, which was produced by catalyzing lactose with β-galactosidase derived from Sporobolomyces singularis and Kluyveromyces lactis. We regard it as a hypoallergic and safe GOS product that does not cause GOS-AL.
Collapse
Affiliation(s)
- Kimiyuki Kaneko
- Yakult Central Institute for Microbiological Research, Tokyo, Japan
| | - Yoko Watanabe
- Yakult Central Institute for Microbiological Research, Tokyo, Japan
| | - Kazumasa Kimura
- Yakult Central Institute for Microbiological Research, Tokyo, Japan
| | | | | | - Masaharu Onoue
- Yakult Central Institute for Microbiological Research, Tokyo, Japan
| |
Collapse
|
15
|
Coulet M, Phothirath P, Constable A, Marsden E, Schilter B. Pre-clinical safety assessment of the synthetic human milk, nature-identical, oligosaccharide Lacto-N-neotetraose (LNnT). Food Chem Toxicol 2013; 62:528-37. [DOI: 10.1016/j.fct.2013.09.018] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2013] [Revised: 08/07/2013] [Accepted: 09/10/2013] [Indexed: 01/08/2023]
|
16
|
Kobayashi T, Takano M, Kaneko K, Onoue M. A one-generation reproduction toxicity study in rats treated orally with a novel galacto-oligosaccharide. Hum Exp Toxicol 2013; 33:814-21. [DOI: 10.1177/0960327113510328] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Galacto-oligosaccharide (GOS) is a naturally occurring prebiotic that beneficially affects the host by selectively stimulating growth and/or activity of one or a limited number of colon bacteria to improve host health. A novel GOS was administered by gavage to male and female Sprague Dawley rats at 0, 500, 1000, and 2000 mg/kg/day for 10 weeks. In males, administration of GOS was initiated prior to mating and continued for 91 days. Females received GOS beginning 2 weeks prior to mating through day 20 of lactation. Parents were observed daily, and body weight (BW) and feed consumption were measured. Vaginal smears, mating behavior, and observation of delivery/lactation were evaluated in parents. Effects on the reproductive function of parents including gonad function, estrous cycle, mating performance, fertility, delivery and lactation, and effects on the growth and development of pups were examined. No deaths occurred, and no general toxicological effects or abnormal reproductive functions were observed in any dose group. Pups were observed at birth and the following measurements were undertaken: BW, external differentiations, sensory functions, and reflex reactions during lactation and just prior to necropsy. No external malformations or differences in the number of pups, in the sex ratio, or BW at birth occurred in any dose group. Growth and development of pups were normal. The No Observed Effect Level for reproductive function of male and female parent animals and for the growth and development of their offspring was at least 2000 mg/kg/day.
Collapse
Affiliation(s)
- T Kobayashi
- Yakult Central Institute for Microbiological Research, Yakult Honsha Co. Ltd, Tokyo, Japan
| | - M Takano
- Gotemba Laboratory, Bozo Research Center Inc., Gotenba, Japan
| | - K Kaneko
- Yakult Central Institute for Microbiological Research, Yakult Honsha Co. Ltd, Tokyo, Japan
| | - M Onoue
- Yakult Central Institute for Microbiological Research, Yakult Honsha Co. Ltd, Tokyo, Japan
| |
Collapse
|
17
|
Nakayama T, Oishi K. Influence of coffee (Coffea arabica) and galacto-oligosaccharide consumption on intestinal microbiota and the host responses. FEMS Microbiol Lett 2013; 343:161-8. [PMID: 23551139 DOI: 10.1111/1574-6968.12142] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2013] [Revised: 03/24/2013] [Accepted: 03/25/2013] [Indexed: 12/14/2022] Open
Abstract
Although studies have reported numerous effects of coffee on human health, few studies have examined its specific effects on gut microbiota. This study aimed to clarify the influence of coffee and galacto-oligosaccharide (GOS) consumption on gut microbiota and host responses. After mice consumed coffee and GOS, their intestines were sampled, and the bacterial counts were measured with quantitative RT-PCR. Results showed that GOS consumption significantly increased total bacteria counts in the proximal colon. Although Escherichia coli and Clostridium spp. counts significantly decreased in the proximal colon, Bifidobacterium spp. counts increased remarkably in the same area. A bacterial growth inhibition assay was also conducted, and the results showed that E. coli growth was inhibited only by a coffee agar. Host responses were also investigated, revealing that coffee and GOS consumption remarkably increased aquaporin8 expression in the proximal colon. In conclusion, coffee has antibiotic effects, and GOS significantly decreased E. coli and Clostridium spp. counts, but increased Bifidobacterium spp. counts remarkably. Aquaporin8 expression was also increased with a mixture of coffee and GOS consumption. This is the first study to demonstrate that coffee consumption can regulate gut microbiota and increase aquaporin8, both of which are necessary for maintaining intestinal balance.
Collapse
Affiliation(s)
- Tatsuya Nakayama
- International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
| | | |
Collapse
|
18
|
Mei GY, Carey CM, Tosh S, Kostrzynska M. Utilization of different types of dietary fibres by potential probiotics. Can J Microbiol 2012; 57:857-65. [PMID: 21958046 DOI: 10.1139/w11-077] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A better understanding of the functionality of probiotics and dietary fibres with prebiotic activity is required for the development of improved synbiotic preparations. In this study, utilization of β(2-1) fructans, galactooligosaccharides, and plant polysaccharides as prebiotics by lactobacilli, bifidobacteria, and pediococci was investigated. Our results demonstrate that prebiotics with linear chains consisting of galactose units are better utilized by probiotics than are those consisting of glucose and fructose units, and the ability of probiotic bacteria to utilize prebiotics is strain-specific. In addition, rye fructooligosaccharides represent a prebiotic fibre that supports the growth of a wide range of probiotic cultures and as such has a potential to improve the successfulness of probiotic treatments. This study also demonstrates dietary fibre utilization by pediococci and provides data supporting the possible use of pediococci as a probiotic in synbiotic combinations.
Collapse
Affiliation(s)
- Gui-Ying Mei
- Agriculture and Agri-Food Canada, Guelph Food Research Center, Canada
| | | | | | | |
Collapse
|
19
|
François IEJA, Lescroart O, Veraverbeke WS, Kubaszky R, Hargitai J, Esdaile DJ, Beres E, Soni MG, Cockburn A, Broekaert WF. Safety Assessment of a Wheat Bran Extract Containing Arabinoxylan-Oligosaccharides: Mutagenicity, Clastogenicity, and 90-Day Rat-Feeding Studies. Int J Toxicol 2010; 29:479-95. [DOI: 10.1177/1091581810374219] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Wheat bran extract (WBE) is a food-grade preparation that is highly enriched in arabinoxylan-oligosaccharides. As part of the safety evaluation of WBE, its genotoxic potential was assessed in a bacterial reverse mutagenicity assay (Ames test) and a chromosome aberration assay on Chinese hamster lung fibroblast cells. These in vitro genotoxicity assays showed no evidence of mutagenic or clastogenic activity with WBE. The safety of WBE was furthermore evaluated in a subchronic toxicity study on rats that were fed a semisynthetic diet (AIN 93G) containing 0.3%, 1.5%, or 7.5% WBE for 13 weeks, corresponding to an average intake of 0.2, 0.9, and 4.4 g/kg body weight (bw) per day, with control groups receiving the unsupplemented AIN 93G, AIN 93G with 7.5% inulin, or AIN 93G with 7.5% wheat bran. Based on this rat-feeding study, the no-observed-adverse-effect level (NOAEL) for WBE was determined as 4.4 g/kg (bw)/d, the highest dose tested.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Andrew Cockburn
- Toxico-Logical Consulting Ltd, Gravesend Farm, Albury Ware, Hertfordshire, SG 11 2LW, UK
| | | |
Collapse
|